Zacks Investment Research upgraded shares of GeoVax Labs Inc. (GOVX ) from N/A to OUTPERFORM on January 22, 2013, with a target price of $1.50.
GOVX is a unique developer for both preventive and therapeutic HIV vaccines. The Company's preventive HIV vaccine is among the only 5 candidates out of more than 90 vaccines entering HVTN Phase I testing chosen to progress to Phase II clinical trials. Both HIV/AIDS vaccine and treatment markets are huge and GOVX has the potential to be a key player in the two markets. Management will continue to create shareholder value by generating new clinical data, bringing in government support and partnership. We believe valuation is attractive with the potential for substantial returns.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on GeoVax Labs Inc. (GOVX ),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment